Theradaptive, a Frederick, MD-based regenerative medicine company developing targeted therapeutics, received funding from the Maryland Stem Cell Research Fund (MSCRF).
The amount of the deal was not disclosed.
The company intends to use the funds to support human clinical trials for its lead product, OsteoAdapt SP.
Led by CEO and Founder Luis Alvarez, Theradaptive is a regenerative medicine company developing therapeutic implants that harness the body’s own stem cells to regenerate tissues. Its proprietary AMP2 technology platform enables localized, sustained delivery of therapeutic proteins to trigger highly targeted regenerative responses.
Its lead clinical program, OsteoAdapt SP, is an investigational bone graft material designed to improve spinal fusion outcomes.
FinSMEs
22/05/2024